[F-18]-Fludeoxyglucose Injection, (“[F-18]-FDG”) is one of the most widely distributed molecular imaging agents in Canada. Used in combination with positron emission tomography (PET), Glucovision enables physicians to non-invasively detect and stage isolated pulmonary nodules and non-small cell lung cancer. PET imaging centres throughout Canada trust CPDC for reliable, daily deliveries of Glucovision.
Sterile Solution for Injection
1 – 540 GBq [F-18]-FDG per vial (Glucovision® Phosphate)
1 – 453 GBq [F-18]-FDG per vial (Glucovision® Citrate)
Glucovision® ([F-18]-FDG Injection) is indicated for use with positron emission tomography in the following:
– Differential diagnosis of isolated indeterminate pulmonary nodules.
– Staging of non-small cell lung cancer.
– Detection of residual or recurrent mass after initial non-small cell lung cancer therapy.
Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph.
Glucovision® should be used only by those health professionals who are appropriately qualified in the use of radioactive prescribed substances in or on humans.
Glucovision® should not be administered to pregnant women unless it is considered that the benefits to be gained outweigh the potential hazards to the fetus.
Glucovision® is excreted in human breast milk. To avoid unnecessary irradiation of the infant, formula feeding should be substituted temporarily for breast feeding.
Monday – Saturday. CPDC delivers to all major Canadian markets on a daily basis. Contact us for the specific availability in your region within Canada.